GLUE – monte rosa therapeutics, inc. (US:NASDAQ)

News

Assessing Monte Rosa Therapeutics (GLUE) Valuation After MRT-2359 Data Update And New Public Offering [Yahoo! Finance]
How Monte Rosa's MRT-2359 Prostate Cancer Data and Funding Plans Could Shape GLUE's Risk-Reward Profile [Yahoo! Finance]
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com